Global Tacrolimus Market Size (2024 - 2029)

The tacrolimus market is projected to experience growth over the forecast period, driven by an increase in organ transplant procedures and enhanced research and development activities in immunosuppression. The market's expansion was initially hindered by the COVID-19 pandemic, which led to a significant decline in transplant surgeries due to lockdowns and social distancing measures. However, the implementation of new treatment guidelines and safety protocols has begun to restore market momentum. The market's size is expected to grow as tacrolimus plays a crucial role in organ transplantation, despite potential challenges posed by the drug's side effects.

Market Size of Global Tacrolimus Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Tacrolimus Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Tacrolimus Market Key Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Tacrolimus Market Analysis

The tacrolimus market is expected to register a CAGR of 5.2% over the forecast period, 2022-2027.

The COVID-19 pandemic has had a significant impact on the growth of the tacrolimus market. Due to stricter lockdowns and stringent social distancing norms, most of the patient population was restricted from undergoing organ transplant procedures globally. This greatly reduced the overall adoption rate of tacrolimus medications worldwide since most of the surgeries and transplantations were either postponed or delayed. For instance, as per the article titled "Kidney Transplantation in COVID Pandemic-A Review of Guidelines" published in the National Library of Medicine, in June 2021, the COVID-19 infection has had a severe impact on transplantation protocols and programs. In 2020, the number of transplants had significantly decreased. Likewise, another article titled "Organ procurement and transplantation during the COVID-19 pandemic" published in the same journal stated that the surge in COVID-19 infections and a startling decline in overall solid-organ transplantation procedures were found to have a clear temporal correlation, according to the researchers. There have been 90.6 percent fewer transplants using deceased donors in France and 51.1 percent fewer in the United States since the COVID-19 epidemic. This decrease was mostly caused by kidney transplantation in both France and the United States, but there was also a sizable impact on heart, lung, and liver transplants as well. In addition, as per the data published by the Global Observatory on Donation and Transplantation, in 2020, there were approximately 17.6% fewer transplants in 2020 as compared with the previous year, that is 2019. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, owing to treatment guidelines and precautionary measures released by several organizations and regulatory bodies for combatting COVID-19 in these procedures, the market is anticipated to gain traction over the coming years.

In addition, the increasing number of transplants worldwide and the surge in research and development activities for immunosuppression are likely to have a positive impact on the growth of the studied market.

Tacrolimus is administered in the management of allograft recipients receiving immunosuppressive drug therapy; thus, it plays a vital role in organ transplantation procedures. According to the data published by the Global Observatory on Donation and Transplantation, in 2020 there were a total of 1,29,681 organ transplants performed worldwide. Similarly, according to Australian and New Zealand Organ Donor Registry (ANZOD) data, in 2021, 657 kidney transplants, 253 liver transplants, 171 lung transplants, and 152 other organ transplant procedures were performed in Australia alone. Such an increase in the number of transplant procedures is expected to boost the acceptance of tacrolimus medications, in turn, driving the market growth over the forecast period.

Moreover, a surge in research and development activities, product launches, and approvals is anticipated to augment the growth of the market over the coming years. For instance, in July 2021, the enrolment for the Phase 1 clinical study for Tacrolimus Inhalation Powder was completed by TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on creating and marketing cutting-edge medical products.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the side effects of the tacrolimus drugs are likely to impede the market growth.

Tacrolimus Industry Segmentation

As per the scope of the report, tacrolimus is a member of the class of drugs referred to as immunosuppressants. In order to reduce allergic reactions and prevent organ transplant rejection, the drug is used to effectively suppress the immune system. The tacrolimus market is segmented by Product Type (Tablets and Capsules, Injections, and Others), Application (Immunosuppression, Dermatitis, and Others), End Users (Hospitals, Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally.

Product Type
Tablets and Capsules
Injections
Others (Ointments, Granules)
By Application
Immunosuppression
Dermatitis
Others (Vitiligo, Eczema)
End Users
Hospitals
Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Tacrolimus Market Size Summary

The tacrolimus market is poised for growth, driven by the increasing number of organ transplants and advancements in immunosuppression research and development. Tacrolimus plays a crucial role in organ transplantation procedures by preventing organ rejection. The market experienced a temporary setback due to the COVID-19 pandemic, which led to a significant decline in transplant procedures globally. However, the market is expected to recover and gain momentum as treatment guidelines and precautionary measures have been implemented. The rise in transplant procedures and ongoing research activities are anticipated to positively impact the market's trajectory over the forecast period.

North America is projected to lead the tacrolimus market, supported by a high number of organ transplants and the presence of key manufacturers. Strategic initiatives, such as product launches and regulatory approvals, are further expected to bolster market growth in the region. The market is characterized by fragmentation, with several global and regional players contributing to its competitive landscape. Companies like GlaxoSmithKline, Pfizer, Astellas Pharma, and others are prominent in the market, engaging in strategic collaborations and product offerings to enhance their market presence. Despite the challenges posed by side effects, the market is set to expand, driven by the increasing acceptance of tacrolimus treatments and ongoing innovations in immunosuppressive therapies.

Explore More

Global Tacrolimus Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Number of Transplants Worldwide

      2. 1.2.2 Surge in Research and Development Activities for Immunosuppression

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects of the Tacrolimus

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 Product Type

      1. 2.1.1 Tablets and Capsules

      2. 2.1.2 Injections

      3. 2.1.3 Others (Ointments, Granules)

    2. 2.2 By Application

      1. 2.2.1 Immunosuppression

      2. 2.2.2 Dermatitis

      3. 2.2.3 Others (Vitiligo, Eczema)

    3. 2.3 End Users

      1. 2.3.1 Hospitals

      2. 2.3.2 Clinics

      3. 2.3.3 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Tacrolimus Market Size FAQs

The Global Tacrolimus Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

Pfizer Inc., Astellas Pharma Inc., Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc. and Biocon Ltd. are the major companies operating in the Global Tacrolimus Market.

Tacrolimus Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)